NCT07334574

Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL

A Safety, Tolerability and Efficacy Study of XP-006 Personalized Tumor mRNA Vaccine for Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Ruijin Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this study is to observe and evaluate the safety and tolerability of the XP-006 personalized tumor mRNA vaccine for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. Secondary objectives focus on evaluating preliminary efficacy through several parameters: XP-006-induced antigen-specific CD4+/CD8+ T cell activation levels, objective remission rate (ORR), complete remission rate (CRR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS).

Conditions

• B-cell Non-Hodgkin's Lymphoma (B-NHL)

Interventions

Type	Name	Description
BIOLOGICAL	Personalized neoantigen tumor vaccine	Neoantigen tumor vaccine

Timeline

• Start date: 2026-01-15
• Primary completion: 2028-01-01
• Completion: 2029-01-01
• First posted: 2026-01-12
• Last updated: 2026-01-13

Locations

1 site across 1 country: China